These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25103068)

  • 41. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
    Maione A; Navaneethan SD; Graziano G; Mitchell R; Johnson D; Mann JF; Gao P; Craig JC; Tognoni G; Perkovic V; Nicolucci A; De Cosmo S; Sasso A; Lamacchia O; Cignarelli M; Manfreda VM; Gentile G; Strippoli GF
    Nephrol Dial Transplant; 2011 Sep; 26(9):2827-47. PubMed ID: 21372254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema.
    Beavers CJ; Dunn SP; Macaulay TE
    Ann Pharmacother; 2011 Apr; 45(4):520-4. PubMed ID: 21427294
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
    Thakur V; Rankin KN; Hartling L; Mackie AS
    Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is there any difference between angiotensin converting enzyme inhibitors and angiotensin receptor blockers for heart failure?
    Rain C; Rada G
    Medwave; 2015 Jul; 15 Suppl 1():e6177. PubMed ID: 26247213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.
    McAlister FA;
    Eur Heart J; 2012 Feb; 33(4):505-14. PubMed ID: 22041554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renin-Angiotensin system blockers and cardiovascular death in kidney recipients.
    Opelz G; Döhler B
    Transplantation; 2014 May; 97(10):e62-3. PubMed ID: 24827898
    [No Abstract]   [Full Text] [Related]  

  • 48. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ACE inhibitors, diabetes and cardiovascular disease.
    Gazis A; Page SR; Cockcroft JR
    Diabetologia; 1998 May; 41(5):595-7. PubMed ID: 9628279
    [No Abstract]   [Full Text] [Related]  

  • 50. An update of the blockade of the renin angiotensin aldosterone system in clinical practice.
    Márquez DF; Ruiz-Hurtado G; Ruilope LM; Segura J
    Expert Opin Pharmacother; 2015; 16(15):2283-92. PubMed ID: 26389772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of dementia by ACE inhibitors and angiotensin receptor blockers - potential but not proven.
    Todd S; McGuinness B; Passmore AP
    Int J Clin Pract; 2010 Nov; 64(12):1595-8. PubMed ID: 20946266
    [No Abstract]   [Full Text] [Related]  

  • 52. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis.
    Bang CN; Greve AM; Køber L; Rossebø AB; Ray S; Boman K; Nienaber CA; Devereux RB; Wachtell K
    Int J Cardiol; 2014 Aug; 175(3):492-8. PubMed ID: 25012498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renin-angiotensin system blockers in cardiac surgery.
    Mangieri A
    J Crit Care; 2015 Jun; 30(3):613-8. PubMed ID: 25813547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. National guidelines for the management of absolute cardiovascular disease risk.
    O'Callaghan CJ; Rong P; Goh MY
    Med J Aust; 2014 May; 200(8):454, 456. PubMed ID: 24794600
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk.
    Dézsi CA; Szentes V
    Am J Cardiovasc Drugs; 2016 Dec; 16(6):399-406. PubMed ID: 27580998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What is the recurrence rate of takotsubo syndrome in patients treated with β-blockers and angiotensin converting enzyme inhibitors/angiotensin receptor blockers?
    Madias JE
    Int J Cardiol; 2016 Sep; 219():394-5. PubMed ID: 27362829
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study.
    Wu HY; Peng CL; Chen PC; Chiang CK; Chang CJ; Huang JW; Peng YS; Tu YK; Chu TS; Hung KY; Chien KL
    PLoS One; 2017; 12(5):e0177654. PubMed ID: 28505194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
    Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
    Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Choice of anti-hypertensive agents in diabetic subjects.
    Patel BM; Mehta AA
    Diab Vasc Dis Res; 2013 Sep; 10(5):385-96. PubMed ID: 23811601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
    Studney D
    Can J Cardiol; 2002 May; 18 Suppl A():3A-6A. PubMed ID: 12045787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.